Living Cell Technologies (LCT) is an Australasian biotechnology company dedicated to discovering, developing, and commercializing novel therapies for serious diseases. Their mission is to improve the wellbeing of individuals suffering from debilitating conditions such as Parkinson's disease, obesity, and migraines. LCT's approach involves harnessing the potential of naturally occurring cells to restore function and provide regenerative treatments.

Their product candidates are designed to address unmet needs in healthcare by utilizing the power of cells and their receptors. One of their innovative products is the NTCELL, an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells specifically targeting Parkinson's disease. This groundbreaking treatment offers hope to patients seeking effective relief.

LCT's commitment to advancing medical research is evident in their numerous research projects, which focus on finding solutions for conditions that lack effective treatments. For those interested in learning more about LCT's business and research efforts, they offer fact sheets that provide a comprehensive summary of their current pipeline and partnership opportunities. Stay updated with the latest news from inside LCT through their insightful and informative newsletters, featuring messages from the executive team, updates on ongoing projects, and details about the company's collaborations.

Living Cell Technologies is at the forefront of pioneering therapies, utilizing the potential of cells to transform the lives of individuals affected by serious diseases